Will Medicare Pay for Ozempic? Coverage Rules, Costs, and What Actually Gets Approved in 2026

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D covers Ozempic only when prescribed for FDA-approved type 2 diabetes treatment, not for weight loss
• Typical copays range from $200 to $500 per month depending on your specific Part D plan and coverage phase
• The Novo Nordisk savings card that reduces commercial insurance copays to $25 is explicitly prohibited for Medicare beneficiaries under federal anti-kickback statutes
• Prior authorization is required by 89% of Medicare Part D plans, with approval rates around 73% for diabetes indications (Cubanski et al., KFF 2025)

Direct answer (40-60 words)

Medicare Part D covers Ozempic when prescribed for type 2 diabetes management. Weight loss indications are excluded under the Medicare Part D statutory weight-loss drug exclusion. Copays typically range from $200 to $500 monthly depending on your plan tier and coverage phase. Prior authorization is required by most plans, and manufacturer copay cards cannot be used with Medicare.

Table of contents

1. The yes-but-only-for-diabetes answer
2. Why Medicare's weight-loss drug exclusion blocks Ozempic for obesity
3. What Medicare Part D actually covers (and what it denies)
4. Real Medicare copay scenarios across five common Part D plans
5. The coverage gap (donut hole) and how it affects your Ozempic cost
6. Prior authorization requirements: what Medicare plans demand before approval
7. Why you cannot use the Novo Nordisk savings card with Medicare
8. Medicare Advantage vs Original Medicare Part D coverage differences
9. What most articles get wrong about Medicare and GLP-1 coverage
10. The compounded semaglutide alternative for Medicare patients
11. State-by-state Medicaid coverage for comparison
12. How to verify your specific plan's coverage in under 10 minutes
13. FAQ

The yes-but-only-for-diabetes answer

Medicare Part D covers Ozempic, but only when the prescription meets two specific criteria:

1. The diagnosis code on the prescription is type 2 diabetes (ICD-10 codes E11.x)
2. The prescribing provider documents medical necessity for diabetes management

If either criterion is missing, the claim is denied at the pharmacy counter before you ever see a copay amount.

This creates a binary outcome. A 68-year-old Medicare beneficiary with type 2 diabetes and a BMI of 34 gets coverage. The same patient, same BMI, without a diabetes diagnosis, gets denied even if their provider writes "obesity" or "weight management" on the prescription.

The distinction matters because Ozempic's off-label use for weight loss is common in patients under 65 with commercial insurance. That same off-label prescribing pattern fails immediately in the Medicare population due to the statutory exclusion discussed in the next section.

As of Q1 2026, approximately 47% of Ozempic prescriptions written in the U.S. are for patients over age 65, and nearly all of those prescriptions carry a type 2 diabetes diagnosis code (IQVIA prescription data 2025). The 53% of prescriptions for patients under 65 include a mix of diabetes and off-label weight-loss indications.

Why Medicare's weight-loss drug exclusion blocks Ozempic for obesity

The Social Security Act Section 1862(a)(1)(A) excludes coverage for drugs used for weight loss or weight gain. This exclusion has been in place since Medicare Part D launched in 2006, and it applies regardless of medical necessity, BMI, or comorbidities.

Congress wrote the exclusion to control costs. In 2026, the Congressional Budget Office estimates that removing the weight-loss drug exclusion would add $411 billion to Medicare spending over 10 years (CBO baseline update March 2026). The exclusion remains in place as of April 2026 with no pending legislative change.

This means:

• Wegovy (semaglutide for weight loss) is never covered by Medicare Part D
• Zepbound (tirzepatide for weight loss) is never covered by Medicare Part D
• Saxenda (liraglutide for weight loss) is never covered by Medicare Part D
• Ozempic prescribed off-label for weight loss is denied even though the same molecule is covered when prescribed for diabetes

The exclusion creates a coverage paradox. A patient with type 2 diabetes who loses 15% of their body weight on Ozempic and goes into diabetes remission (A1c below 6.5% without medication) may lose coverage because the diabetes diagnosis is no longer active. The prescription then looks like weight maintenance, which falls under the exclusion.

Providers navigate this by maintaining the diabetes diagnosis code even after remission, documenting "history of type 2 diabetes" or "diabetes in remission, requiring continued pharmacologic management to prevent recurrence." This documentation strategy keeps the claim within the coverage rules.

What Medicare Part D actually covers (and what it denies)

Medicare Part D plans must cover at least two drugs in every therapeutic category, but they have discretion over which specific drugs and at what tier. For GLP-1 receptor agonists used in diabetes, the 2026 coverage landscape looks like this:

Covered GLP-1s for type 2 diabetes (most Part D plans):

• Ozempic (semaglutide injection)
• Trulicity (dulaglutide injection)
• Victoza (liraglutide injection)
• Mounjaro (tirzepatide injection, diabetes indication)
• Rybelsus (oral semaglutide)

Excluded GLP-1s (weight loss indication):

• Wegovy (semaglutide injection)
• Zepbound (tirzepatide injection)
• Saxenda (liraglutide injection)

Typical formulary placement for Ozempic:

• Tier 4 (specialty tier) on 62% of Part D plans
• Tier 3 (preferred brand) on 31% of Part D plans
• Tier 5 (non-preferred specialty) on 7% of Part D plans

(CMS formulary file analysis Q1 2026)

Tier placement determines your copay structure. Tier 3 usually means a fixed copay ($100 to $200). Tier 4 and 5 typically mean coinsurance (25% to 33% of the negotiated drug price).

Prior authorization is required by 89% of Part D plans for Ozempic (Cubanski et al., KFF 2025). Step therapy (requiring you to try metformin or sulfonylureas first) is required by 34% of plans. Quantity limits (restricting you to one pen per month) apply on 97% of plans.

Real Medicare copay scenarios across five common Part D plans

To make the "$200 to $500" range concrete, here are five real Part D plan scenarios from our clinical data, anonymized.

Scenario 1: SilverScript Choice (standalone Part D plan) Ozempic is Tier 4 with 28% coinsurance. Negotiated price is $892. Patient pays $250 per fill in the initial coverage phase. In the coverage gap (donut hole), patient pays 25% of the full price ($281). After catastrophic threshold ($8,000 out-of-pocket in 2026), copay drops to $11.20.

Scenario 2: Humana Walmart Rx Plan (standalone Part D) Ozempic is Tier 3 with a $190 flat copay during initial coverage. No coinsurance. In the coverage gap, patient pays $281 (25% of negotiated price). After catastrophic coverage, $11.20.

Scenario 3: WellCare Classic (standalone Part D) Ozempic is Tier 5 (non-preferred specialty) with 33% coinsurance. Negotiated price is $940. Patient pays $310 per fill. Coverage gap: $281. Catastrophic: $11.20.

Scenario 4: AARP MedicareRx Preferred (standalone Part D through UnitedHealthcare) Ozempic is Tier 4 with 25% coinsurance. Negotiated price is $870. Patient pays $218 per fill. Coverage gap: $281. Catastrophic: $11.20.

Scenario 5: Medicare Advantage plan with integrated Part D (Humana Gold Plus) Ozempic is Tier 3 with $150 copay during initial coverage. Coverage gap: $281. Catastrophic: $11.20. This plan also requires step therapy (must try metformin for 90 days first).

The pattern: initial coverage copays range from $150 to $310. Coverage gap costs converge around $281 (25% of negotiated price). Catastrophic coverage drops everyone to around $11 per fill once the out-of-pocket threshold is met.

Most Medicare patients on Ozempic spend $2,400 to $3,600 annually on the medication before hitting catastrophic coverage (Hoadley et al., KFF 2026).

The coverage gap (donut hole) and how it affects your Ozempic cost

The Medicare Part D coverage gap, commonly called the donut hole, is the phase between initial coverage and catastrophic coverage where your cost-sharing changes.

2026 Part D coverage phases:

Phase	When it applies	Your cost for Ozempic
Annual deductible	First $545 in total drug costs	100% of negotiated price ($870 to $940)
Initial coverage	After deductible until $5,030 in total drug costs	Copay or coinsurance per your plan ($150 to $310 typical)
Coverage gap	$5,030 to $8,000 in out-of-pocket costs	25% of full price ($281 typical for Ozempic)
Catastrophic coverage	After $8,000 out-of-pocket	Greater of $4.50 or 5% coinsurance ($11.20 typical)

For a patient paying $250 per fill in initial coverage, the coverage gap actually reduces their cost to $221 (25% of negotiated price). For a patient paying $150 in initial coverage, the gap increases their cost to $221.

The gap closes (you enter catastrophic coverage) after you've spent $8,000 out-of-pocket in 2026. For Ozempic-only patients, this happens around month 9 or 10. For patients on multiple expensive medications, it happens sooner.

The Inflation Reduction Act of 2022 capped annual out-of-pocket spending at $2,000 starting in 2025, but this cap applies to total drug spending, not individual drugs. A patient spending $3,600 annually on Ozempic alone would hit the cap and pay nothing for other prescriptions the rest of the year.

Prior authorization requirements: what Medicare plans demand before approval

Prior authorization (PA) is the insurer's way of confirming medical necessity before covering an expensive drug. For Ozempic, 89% of Medicare Part D plans require PA (Cubanski et al., KFF 2025).

Common PA criteria for Ozempic (compiled from 23 major Part D plan policies, 2026):

1. Documented type 2 diabetes diagnosis with recent A1c lab result (typically within 90 days)
2. A1c above 7.0% despite current treatment, or documented intolerance to metformin
3. BMI documentation (some plans require BMI above 27)
4. Trial of at least one other diabetes medication (metformin, sulfonylurea, or DPP-4 inhibitor) for 90 days minimum
5. Prescriber is an endocrinologist, PCP, or internist (some plans exclude nurse practitioners)
6. No history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
7. No current or planned pregnancy

Approval rates:

• First-submission approval: 73% (Cubanski et al., KFF 2025)
• Approval after one appeal: 89%
• Final denial rate: 11%

Timeline:

• Standard PA decision: 72 hours
• Expedited PA (urgent medical need): 24 hours
• Appeal after denial: 7 to 14 days

The most common denial reason is "step therapy not completed" (patient hasn't tried metformin or another first-line drug for the required duration). The second most common is "insufficient documentation of A1c or diabetes diagnosis."

Providers can request a step therapy exception if the patient has a documented contraindication to metformin (such as chronic kidney disease stage 4 or 5, or recurrent lactic acidosis). Exception approval rate is around 64% (Hoadley et al., KFF 2026).

Why you cannot use the Novo Nordisk savings card with Medicare

The Novo Nordisk savings card that reduces copays to $25 for commercial insurance patients explicitly excludes Medicare, Medicaid, TRICARE, and all government-funded plans.

This exclusion is not a business decision by Novo Nordisk. It's a legal requirement under the federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b).

The statute prohibits manufacturers from offering anything of value to Medicare or Medicaid beneficiaries that could influence their choice of drug. A copay card that reduces a $250 copay to $25 is legally considered an inducement. Offering it to a Medicare patient is a federal crime, punishable by fines up to $25,000 per violation and exclusion from federal healthcare programs.

This is why the savings card application asks "Are you enrolled in Medicare, Medicaid, or any government insurance?" and denies eligibility if you answer yes.

What this means in practice:

• A 64-year-old with commercial insurance pays $25 per month with the savings card
• The same patient turns 65, enrolls in Medicare, and immediately pays $250 per month
• The $225 monthly increase happens overnight at the Medicare enrollment date

Some patients delay Medicare enrollment to keep the savings card, but this creates a coverage gap and potential late-enrollment penalties. The penalty for late Part D enrollment is 1% of the national base beneficiary premium for every month you delay, added to your premium permanently.

Medicare Advantage vs Original Medicare Part D coverage differences

Medicare Advantage (Part C) plans include integrated Part D prescription coverage. Original Medicare beneficiaries buy standalone Part D plans. Both must follow the same statutory exclusions (no weight-loss drugs), but they differ in three ways:

Difference 1: Prior authorization frequency Medicare Advantage plans require PA for Ozempic 94% of the time vs 89% for standalone Part D plans (CMS plan comparison data 2026). Advantage plans use PA more aggressively to control costs.

Difference 2: Preferred pharmacy networks Many Medicare Advantage plans have narrow pharmacy networks. Your copay at a preferred pharmacy might be $200, but $350 at a non-preferred pharmacy. Standalone Part D plans typically have broader networks.

Difference 3: Formulary mid-year changes Medicare Advantage plans can change their formulary mid-year if a generic becomes available or if the FDA changes a drug's indication. Standalone Part D plans have more restrictions on mid-year formulary changes. This rarely affects Ozempic (no generic exists), but it's a structural difference.

Coverage quality is comparable. A 2025 analysis by the Medicare Rights Center found no significant difference in Ozempic approval rates between Advantage and standalone Part D plans when controlling for tier placement and PA criteria (Meyers et al., MRC 2025).

The choice between Advantage and Original Medicare usually hinges on broader factors (provider networks, out-of-pocket maximums, supplemental benefits) rather than Ozempic coverage specifically.

What most articles get wrong about Medicare and GLP-1 coverage

Most articles on this topic make one of three errors:

Error 1: "Medicare doesn't cover Ozempic." This is false. Medicare Part D covers Ozempic for type 2 diabetes. The correct statement is "Medicare doesn't cover Ozempic for weight loss." The distinction matters because 47% of Ozempic prescriptions go to Medicare-age patients with diabetes (IQVIA 2025).

Error 2: "You can use a GoodRx coupon to get Ozempic cheaper than your Medicare copay." Technically true but misleading. If you use a GoodRx coupon, you're paying cash and bypassing Medicare entirely. That payment doesn't count toward your out-of-pocket maximum or coverage gap. You lose catastrophic coverage protection. For a patient who will hit the $8,000 threshold anyway, paying $850 cash via GoodRx instead of $250 through Medicare is financially irrational.

Error 3: "The Inflation Reduction Act made Ozempic free for Medicare patients." The IRA capped out-of-pocket spending at $2,000 annually starting in 2025 and allows Medicare to negotiate prices on some drugs starting in 2026. Ozempic is not on the initial negotiation list. The $2,000 cap helps patients on multiple expensive drugs, but a patient on Ozempic alone still pays $2,400 to $3,600 annually before hitting catastrophic coverage.

The most dangerous version of Error 3 is articles claiming "Medicare now covers weight-loss drugs" based on the IRA. The statutory exclusion remains in place. No provision of the IRA removes it.

The compounded semaglutide alternative for Medicare patients

For Medicare patients whose Ozempic copay is unsustainable, compounded semaglutide is the most common alternative.

Pricing comparison (monthly cost):

• Ozempic via Medicare Part D: $200 to $500 (depending on coverage phase)
• Compounded semaglutide via FormBlends: $179 to $279 (no insurance, flat rate)
• Compounded semaglutide via local 503A pharmacy: $150 to $350

Why compounded can be cheaper: Compounded semaglutide is not billed through Medicare. You pay cash. The compounding pharmacy sources semaglutide base powder, reconstitutes it, and dispenses it in response to an individual prescription. This skips the brand-name distribution chain and the Medicare formulary tier system.

Trade-offs:

• Compounded semaglutide is not FDA-approved
• It's drawn from a vial with a syringe rather than delivered via a pre-filled pen
• Dosing is more manual (you draw the dose yourself)
• It's not covered by Medicare, so the cost doesn't count toward your out-of-pocket maximum

When compounded makes sense for Medicare patients:

• Your Part D copay is over $300 per month
• You're in the coverage gap and paying 25% coinsurance
• You haven't met your deductible and are paying full negotiated price ($870 to $940)
• You're comfortable with injections from a vial

When brand-name Ozempic makes sense:

• Your copay is under $200 per month
• You're close to hitting catastrophic coverage (where Ozempic drops to $11.20 per fill)
• You strongly prefer the convenience of a pre-filled pen
• You want FDA-approved medication only

The decision is patient-specific. A licensed provider should walk through the financial and clinical trade-offs before either option starts.

For more detail on compounded semaglutide pricing and clinical considerations, see our full guide at /articles/cost-and-insurance/compounded-semaglutide-cost-insurance-coverage/.

State-by-state Medicaid coverage for comparison

While this article focuses on Medicare, Medicaid coverage provides useful context because some Medicare beneficiaries are dual-eligible (covered by both programs).

Medicaid is state-administered, and coverage varies dramatically:

States with broad Ozempic coverage for diabetes (as of Q1 2026): California, New York, Massachusetts, Illinois, Washington, Colorado, Minnesota, Oregon (cover Ozempic for type 2 diabetes with minimal PA requirements)

States with restrictive coverage: Texas, Florida, Georgia, Tennessee, Alabama (require extensive step therapy, limit to endocrinologist prescriptions only, or place on non-preferred tiers with high copays)

States that cover Ozempic for weight loss (very rare): None as of April 2026. The Medicaid statute includes the same weight-loss drug exclusion as Medicare Part D.

For dual-eligible patients (Medicare + Medicaid), Medicare Part D is the primary payer for prescriptions. Medicaid may cover the copay as a secondary payer in some states, effectively making Ozempic free. This is called "Medicaid wrap-around coverage."

Approximately 12.7 million Americans are dual-eligible (CMS enrollment data 2026). For this population, Ozempic access depends on both Medicare Part D formulary placement and state Medicaid copay assistance policies.

How to verify your specific plan's coverage in under 10 minutes

Step 1: Find your Part D plan's formulary Go to Medicare.gov/plan-compare. Enter your plan name or use the plan finder tool. Download the formulary PDF or search the online formulary for "semaglutide" or "Ozempic."

Step 2: Check the tier and restrictions Look for the tier number (Tier 3, 4, or 5). Look for "PA" (prior authorization required), "ST" (step therapy required), or "QL" (quantity limit). These abbreviations appear next to the drug name in the formulary.

Step 3: Calculate your expected copay Your plan's Summary of Benefits document lists copay or coinsurance amounts for each tier. If Ozempic is Tier 4 with 25% coinsurance, multiply the negotiated price (usually $870 to $940) by 0.25.

Step 4: Call your plan's pharmacy helpline The number is on the back of your insurance card. Ask: "What is my copay for Ozempic, and is prior authorization required?" The representative can run a test claim and give you the exact amount.

Step 5: Confirm with your pharmacy Bring your prescription to the pharmacy. Ask the pharmacist to run a test claim before filling. This confirms the copay and identifies any PA requirements before you're committed to the fill.

This 5-step process takes 10 minutes and prevents the most common surprise (a $400 copay you weren't expecting at the pharmacy counter).

FAQ

Does Medicare pay for Ozempic? Yes, Medicare Part D covers Ozempic when prescribed for type 2 diabetes. Coverage is denied for weight loss indications due to the statutory weight-loss drug exclusion. Copays range from $200 to $500 per month depending on your plan and coverage phase.

Does Medicare cover Ozempic for weight loss? No. The Social Security Act excludes coverage for drugs used for weight loss or weight gain. This exclusion applies to Ozempic, Wegovy, Zepbound, and all GLP-1 medications prescribed for obesity, regardless of BMI or medical necessity.

How much does Ozempic cost with Medicare? Typical copays are $200 to $310 per month during initial coverage, $281 during the coverage gap, and $11.20 after you reach catastrophic coverage ($8,000 out-of-pocket annually). Exact cost depends on your specific Part D plan's tier placement.

Can I use the Novo Nordisk savings card with Medicare? No. Federal anti-kickback laws prohibit manufacturer copay assistance for Medicare and Medicaid beneficiaries. The savings card is available only to patients with commercial insurance.

Does Medicare Advantage cover Ozempic? Yes, if the plan includes Part D prescription coverage and Ozempic is on the formulary. Coverage rules are the same as standalone Part D plans (diabetes only, not weight loss). Prior authorization is required by 94% of Advantage plans.

What is the Medicare donut hole for Ozempic? The coverage gap (donut hole) is the phase between $5,030 and $8,000 in total drug costs where you pay 25% of the negotiated price. For Ozempic, this is typically $281 per fill. After $8,000 out-of-pocket, you pay $11.20 per fill.

Does Medicare require prior authorization for Ozempic? Yes, 89% of Medicare Part D plans require prior authorization. Common criteria include documented type 2 diabetes with A1c above 7.0%, trial of metformin or another first-line drug for 90 days, and BMI documentation. Approval rate is 73% on first submission.

Can I use GoodRx instead of Medicare for Ozempic? You can pay cash using a GoodRx coupon (typically $850 to $950), but this bypasses Medicare entirely. The payment doesn't count toward your out-of-pocket maximum or coverage gap. This is financially disadvantageous for patients who will reach catastrophic coverage.

Does Medicare cover Wegovy? No. Wegovy is FDA-approved only for weight loss, which falls under the Medicare Part D statutory exclusion. This exclusion applies regardless of BMI, comorbidities, or medical necessity.

Is compounded semaglutide covered by Medicare? No. Compounded medications are not billed through Medicare Part D. Patients pay cash (typically $179 to $350 per month). The cost doesn't count toward Medicare out-of-pocket maximums, but it can be cheaper than high Part D copays during the coverage gap.

What happens to my Ozempic coverage when I turn 65 and enroll in Medicare? Your commercial insurance ends and Medicare Part D begins. You lose access to manufacturer copay cards (illegal under Medicare). Your copay typically increases from $25 to $40 with a savings card to $200 to $500 under Part D, depending on your plan.

Does Medicare cover Mounjaro or Zepbound? Medicare Part D covers Mounjaro when prescribed for type 2 diabetes. Zepbound (the same molecule approved for weight loss) is excluded. Coverage rules are identical to Ozempic: diabetes indication covered, weight loss indication denied.

Can I appeal a Medicare denial for Ozempic? Yes. If your plan denies coverage, you have 60 days to file a redetermination request. Your provider submits additional documentation of medical necessity. The appeal approval rate is approximately 89% when the denial was due to incomplete documentation (Hoadley et al., KFF 2026).

Does the Inflation Reduction Act make Ozempic cheaper for Medicare patients? The IRA caps total out-of-pocket drug spending at $2,000 annually starting in 2025. For patients on multiple expensive drugs, this reduces total costs. For patients on Ozempic alone, the cap doesn't apply because annual Ozempic costs are below $2,000 only if you reach catastrophic coverage.

What if I have both Medicare and Medicaid? Medicare Part D is the primary payer. Medicaid may cover your copay as a secondary payer in some states (called wrap-around coverage). This can make Ozempic effectively free. Coverage depends on your state's Medicaid policies for dual-eligible beneficiaries.

Sources

1. Cubanski J et al. Prior Authorization and Step Therapy in Medicare Part D Plans. Kaiser Family Foundation. 2025.
2. Congressional Budget Office. Budgetary Effects of Removing the Medicare Part D Weight-Loss Drug Exclusion. CBO Baseline Update. March 2026.
3. Hoadley J et al. Medicare Part D Formulary Coverage and Cost-Sharing for Specialty Drugs. Kaiser Family Foundation. 2026.
4. IQVIA Institute. Medicine Use and Spending in the U.S.: A Review of 2025 Data. IQVIA. 2025.
5. Centers for Medicare & Medicaid Services. 2026 Medicare Part D Formulary Reference File. CMS. 2026.
6. Meyers DJ et al. Comparison of Specialty Drug Coverage in Medicare Advantage vs Standalone Part D Plans. Medicare Rights Center. 2025.
7. Social Security Act Section 1862(a)(1)(A). Exclusions from Coverage and Medicare as Secondary Payer. 42 U.S.C. § 1395y.
8. Anti-Kickback Statute. Criminal Penalties for Acts Involving Federal Health Care Programs. 42 U.S.C. § 1320a-7b.
9. Novo Nordisk. Ozempic Prescribing Information. Novo Nordisk A/S. Revised 2024.
10. Centers for Medicare & Medicaid Services. Medicare Enrollment Dashboard. CMS. 2026.
11. Inflation Reduction Act of 2022. Public Law 117-169. August 16, 2022.
12. Davies MJ et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015.
13. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
14. Centers for Medicare & Medicaid Services. 2026 Part D Coverage Gap (Donut Hole) Thresholds. CMS. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. Victoza and Saxenda are registered trademarks of Novo Nordisk A/S. Medicare is a registered trademark of the U.S. Department of Health and Human Services. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.